RxPack, a new device company formed from a joint venture between Lindal and Coster in 2021, has announced the appointment of inhaler development specialist Alberto Colombo as Head of R&D and Customer Technical Support.
Colombo was most recently a device development specialist at Chiesi, where he managed MDI projects,and previously spent approximately 10 years in quality assurance and R&D at device developer Plastiape (now Berry Global), where he worked on DPIs for the European and US markets.
According to the RxPack announcement, Colombo “made a valuable contribution supporting the transition to green propellants on which the industry is placing great attention and expectations” during his time at Chiesi. In 2019, Chiesi announced that it intended to launch a lower carbon footprint metered dose inhaler by the end of 2025 and that it had signed an agreement with Koura for a supply of HFA 152a propellant.
The company said, “RxPack welcomes Alberto: combining his skills with those already present and consolidated in the company, together with the continuous investments in technological processes, clean rooms, and regulatory rigor, are the basis for successfully interpreting and supporting the needs of our customers and patients.”
Read the RxPack LinkedIn announcement
